Movement Alert｜Revolution Medicines, Inc. Falls 5.28% in Regular Trading, Biotech Sector Weakness Pressures Shares

Market Focus

1 hour ago

On October 8, Revolution Medicines, Inc. fell 5.28% in regular trading, trading at $190.24/share, with Turnover of $65.13 million.

The decline comes amid broad weakness across the biotechnology sector, with notable losses in peer names including Argenx SE down 11.98%, Twist Bioscience Corp down 4.25%, Natera down 2.13%, AbbVie down 0.26%, and Moderna, Inc. down 0.1%.

Revolution Medicines, Inc., a clinical-stage oncology company, develops novel targeted therapies for RAS-addicted cancers. Its pipeline includes RAS(ON) inhibitors such as RMC-6236, RMC-6291, and RMC-9805, as well as earlier-stage compounds targeting additional RAS variants.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/news/1152254217"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152254217\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152254217?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-08 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152254217","market":"us","top_or_hot":-1,"title":"Movement Alert｜Revolution Medicines, Inc. Falls 5.28% in Regular Trading, Biotech Sector Weakness Pressures Shares","media":"Market Focus","content":"<p><p>On October 8, Revolution Medicines, Inc. fell 5.28% in regular trading, trading at $190.24/share, with Turnover of $65.13 million.</p><p>The decline comes amid broad weakness across the biotechnology sector, with notable losses in peer names including Argenx SE down 11.98%, Twist Bioscience Corp down 4.25%, Natera down 2.13%, AbbVie down 0.26%, and Moderna, Inc. down 0.1%.</p><p>Revolution Medicines, Inc., a clinical-stage oncology company, develops novel targeted therapies for RAS-addicted cancers. Its pipeline includes RAS(ON) inhibitors such as RMC-6236, RMC-6291, and RMC-9805, as well as earlier-stage compounds targeting additional RAS variants.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Revolution Medicines, Inc. Falls 5.28% in Regular Trading, Biotech Sector Weakness Pressures Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Revolution Medicines, Inc. Falls 5.28% in Regular Trading, Biotech Sector Weakness Pressures Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-08 21:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 8, Revolution Medicines, Inc. fell 5.28% in regular trading, trading at $190.24/share, with Turnover of $65.13 million.</p><p>The decline comes amid broad weakness across the biotechnology sector, with notable losses in peer names including Argenx SE down 11.98%, Twist Bioscience Corp down 4.25%, Natera down 2.13%, AbbVie down 0.26%, and Moderna, Inc. down 0.1%.</p><p>Revolution Medicines, Inc., a clinical-stage oncology company, develops novel targeted therapies for RAS-addicted cancers. Its pipeline includes RAS(ON) inhibitors such as RMC-6236, RMC-6291, and RMC-9805, as well as earlier-stage compounds targeting additional RAS variants.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1152254217","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152254217","pubTimestamp":1791467901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 8, Revolution Medicines, Inc. fell 5.28% in regular trading, trading at $190.24/share, with Turnover of $65.13 million.The decline comes amid broad weakness across the biotechnology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"走势警报|Revolution Medicines, Inc. 常规交易中下跌 5.28%，生物技术板块疲软给股价带来压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"On October 8, Revolution Medicines, Inc. fell 5.28% in regular trading, trading at $190.24/share, with Turnover of $65.13 million.The decline comes amid broad weakness across the biotechnology sector, with notable losses in peer names including Argenx SE down 11.98%, Twist Bioscience Corp down 4.25%, Natera down 2.13%, AbbVie down 0.26%, and Moderna, Inc. down 0.1%.Revolution Medicines, Inc., a clinical-stage oncology company, develops novel targeted therapies for RAS-addicted cancers. Its pipeline includes RAS(ON) inhibitors such as RMC-6236, RMC-6291, and RMC-9805, as well as earlier-stage compounds targeting additional RAS variants.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}